An Update on the Management of Myeloma



Melissa Alsina, MD

Head, Myeloma BMT-CI Program

H. Lee Moffitt Cancer Center

Outline

- Redefining Goal of First Line of Therapy
- Updates on Induction therapy for TE patients 3 vs 4 drugs? Perseus, Iskia studies
- Updates on relapse/refractory myeloma CAR-T Bispecific Antibodies

Milestones in Multiple Myeloma Drug Approvals






Image adapted from Kyle R, et al. *Blood.* 2008;111:2962; Raje N, et al. *N Engl J Med.* 2019;380:1726; Li W, et al. *Circulation.* 2016;133:908.

The Good News



Shah, U.A. and S. Mailankody, BMJ, 2020

The not so good news...




First Shot = Best Shot

- In non-transplant patients, attrition rates are high and remain steady through 5th LOT
- · In transplant patients, attrition rates were lower, but increased with each successive LOT

LOT	Frequency, N	Attrition, %	Deaths, <i>n</i> (%)	No subsequent treatment in follow-up, n (%)
Non-	transplant			
1	22,062	-	2841 (12.9)	9716 (44.0)
2	9505	56.9	1155 (12.2)	3168 (33.3)
3	5182	45.5	636 (12.3)	1575 (30.3)
4	2971	42.7	364 (12.3)	901 (30.3)
5	1706	42.6	209 (12.3)	508 (29.8)
Trans	plant			
1	2763	4	36 (1.3)	543 (19.6)
2	2184	21.0	60 (2.7)	613 (28.1)
3	1511	30.8	63 (4.2)	494 (32.7)
4	954	36.9	60 (6.3)	276 (28.9)
5	618	35.2	49 (7.9)	180 (29.1)

Table 4 Attrition rates by LOT




Mean Treatment Duration by LOT in Patients with NDMM

LOT Line of therapy, SD Standard deviation

Response status and patient outcomes.


Deeper responses = better outcomes - *Not new news*- **2011**




Prognostic influence of 6 response categories on PFS/OS

Martinez-Lopez J, et al. Blood. 2011;118:529-534.

Redefining the Goal of Therapy: Minimal Residual Disease (MRD) status and MM outcomes.



Phase 3 DETERMINATION: MRD/PFS by MRD




Richardson P, et al. ASCO 2022. Richardson P, et al. N Engl J Med. 2022;387:132-147.

Why is MRD important?

Multiple studies and meta-analyses have shown the **strong association** between MRD negativity and PFS/OS


Refining Induction Therapy



GRIFFIN: Quad Regimen 2024 SOC for Fit Patients

Addition of daratumumab to RVd improves depth of response and progression-free survival in transplant-eligible NDMM

- Ph 3 Quad Regimens at ASH 2023:
- PERSEUS (D-RVd)
- IsKia (Isa-KRd)




(0) (9) (22) (27) (28) (30) (35) (37) (37) (40) (42) (46) (48) (50) (51) (53) (60) (73) (82) (82) (85)

(5) (8) (10) (10) (12) (13) (15) (15) (17) (27) (35) (36) (38) (40) (48) (70) (81) (90) (93)

D-RVd 104 98 94 90 90 89 86 85 81 81 79 68 59 58 56 54 45 23 12 3 0

RVd 103 93 77 72 70 68 63 61 59 53 51 46 42 39 35 33 25

PERSEUS: Study Design



PERSEUS: Demographics and Clinical Characteristics

	D-VRd (n = 355)	VRd (n = 354)		D-VRd (n = 355)	VRd (n = 354)
Age	Contraction and		ISS stage, ^c n (%)		
Median (range), years	61.0 (32-70)	59.0 (31-70)	N	355	353
Category, n (%)	-		1	186 (52.4)	178 (50.4)
<50 years	54 (15.2)	54 (15.3)	, II	114 (32.1)	125 (35.4)
≥50 and <65 years	207 (58.3)	213 (60.2)	III	55 (15.5)	50 (14.2)
≥65 years	94 (26.5)	87 (24.6)	Number of extramedullary		Ī
Male, n (%)	211 (59.4)	205 (57.9)	plasmacytomas, n (%)	1	
ECOG PS,ª n (%)			0	340 (95.8)	338 (95.5)
0	221 (62.3)	230 (65.0)	≥1	15 (4.2)	16 (4.5)
1	114 (32.1)	108 (30.5)	Cytogenetic profile, ^d n (%)		
2	19 (5.4)	16 (4.5)	Standard risk	264 (74.4)	266 (75.1)
3	1 (0.3)	0	High risk	76 (21.4)	78 (22.0)
MM diagnosis, n (%)		1	Indeterminate	15 (4.2)	10 (2.8)
N	354	352			
CRAB criteria only ^b	125 (35.3)	113 (32.1)			
Biomarkers of malignancy only	52 (14.7)	65 (18.5)			
CRAB criteria and biomarkers of malignancy	177 (50.0)	174 (49.4)			

D-VRd and VRd treatment arms were well balanced

PERSEUS: Patient Disposition

٠

Median follow-up: 47.5 months

	D-VRd (n = 351)	VRd (n = 347)		100 90]	89.5%	86.2%	89.7%	87.0%	91.7%	86.5%
Patients who discontinued study treatment, n (%)	91 (25.9)	188 (54.2)		80	-						
Reason for discontinuation, n (%)			Its	70	1						
Adverse event	32 (9.1)	78 (22.5)	atier	60	1						
Progressive disease	29 (8.3)	72 (20.7)	of patients	50 40]						
Patient refused further study treatment	10 (2.8)	14 (4.0)	% 0	30							
Death	9 (2.6)	11 (3.2)		20	-						
Physician decision	8 (2.3)	9 (2.6)		10	+						
Lost to follow-up	3 (0.9)	2 (0.6)		0	L						
Non-compliance with study drug	0	1 (0.3)				Comp			eived		ered
Other	0	1 (0.3)					dation	AS	SCT	mainte	enance
								D-VRd	■ VRd		


Among patients receiving maintenance (D-VRd, n = 322; VRd, n = 300), 81 (25.2%) patients in the D-VRd group and 58 (19.3%) patients in the VRd group discontinued lenalidomide during maintenance

PERSEUS: Stem Cell Collection and Transplantation

	D-VRd	VRd
Patients receiving plerixafor for mobilization, n (%) ^a	134 (40.0)	72 (22.7)
Median CD34 ⁺ cells collected, 10 ⁶ /kg ^b	5.5	7.4
Patients receiving transplant, n (%) ^c	315 (89.7)	302 (87.0)
Patients achieving hematopoietic reconstitution, n (%) ^d	314 (99.7)	300 (99.3)
Median time to engraftment, days ^e	14	14


Stem cell mobilization and collection were feasible with D-VRd
D-VRd did not impact the ability to receive transplant or engraftment

PERSEUS: Overall ≥CR Rates



- Overall ≥CR rate was significantly higher with D-VRd versus VRd
- >CR rate was improved with D-VRd versus VRd across subgroups

PERSEUS: Overall and Sustained MRD Neg Rates




Deep and durable MRD negativity was achieved with D-VRd

 64% (207/322) of patients receiving maintenance in the D-VRd group discontinued DARA after achieving sustained MRD negativity per protocol^d


PERSEUS: MRD-negativity Rates Over Time

•



 Rates of MRD negativity improved during maintenance
 The absolute difference between D-VRd and VRd widened over time and is most evident at the deeper threshold of 10⁻⁶

PERSEUS: Progression-Free Survival




58% reduction in the risk of progression or death in patients receiving D-VRd

PERSEUS: PFS in Prespecified Subgroups

Subgroup	D-VRd no. of progression eve	VRd ents or deaths/total no.	HR (95% CI)	
Sex		all a second		
Male	36/211	61/205		0.51 (0.34-0.77)
Female	14/144	42/149		0.29 (0.16-0.53)
Age				
<65 y	30/261	84/267		0.30 (0.20-0.46)
≥65 y	20/94	19/87	⊢	0.97 (0.52-1.81)
Race				
White	47/330	95/323		0.42 (0.30-0.60)
Other	3/25	8/31	⊢ − − − − − − − − − −	0.40 (0.11-1.50)
ISS stage				,
1	18/186	35/178		0.46 (0.26-0.81)
il	19/114	43/125	!	0.37 (0.22-0.64)
iir	13/55	25/50		0.42 (0.22-0.83)
Type of MM	13,35	23/30		0.12 (0.22 0.05)
lgG	28/204	58/185	⊢ ●	0.36 (0.23-0.57)
Non-lgG	13/78	31/96		0.46 (0.24-0.88)
Cytogenetic risk	15,70	51750		0.40 (0.24 0.00)
Standard risk	25/264	62/266	⊢	0.35 (0.22-0.56)
High risk	24/76	38/78		0.59 (0.36-0.99)
Indeterminate	1/15	3/10		0.16 (0.02-1.56)
ECOG PS	1115	5/10		0.10 (0.02 1.50)
0	28/221	60/230		0.42 (0.27-0.66)
≥1	22/134	43/124		0.41 (0.25-0.69)
<u> </u>	22/154	43/124		0.41 (0.25-0.05)
		+	0.1 1 10	
			Favors D-VRd Favors VRd	

PFS was improved with D-VRd versus VRd across clinically relevant subgroups

PERSEUS: Overall Survival




OS data trend favorably for D-VRd

PERSEUS: Safety

		VRd 351)	VRd (n = 347)		
Event, n (%) ^a	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4	
HEMATOLOGIC				and the second se	
Neutropenia	243 (69.2)	218 (62.1)	204 (58.8)	177 (51.0)	
Thrombocytopenia	170 (48.4)	102 (29.1)	119 (34.3)	60 (17.3)	
Anemia	78 (22.2)	21 (6.0)	72 (20.7)	22 (6.3)	
Febrile neutropenia	34 (9.7)	33 (9.4)	38 (11.0)	35 (10.1)	
NON-HEMATOLOGIC					
Diarrhea	214 (61.0)	37 (10.5)	188 (54.2)	27 (7.8)	
Peripheral sensory neuropathy	188 (53.6)	15 (4.3)	179 (51.6)	14 (4.0)	
Constipation	119 (33.9)	8 (2.3)	118 (34.0)	6 (1.7)	
Pyrexia	111 (31.6)	8 (2.3)	109 (31.4)	9 (2.6)	
Insomnia	95 (27.1)	8 (2.3)	61 (17.6)	6 (1.7)	
Asthenia	94 (26.8)	12 (3.4)	89 (25.6)	9 (2.6)	
Cough	85 (24.2)	1 (0.3)	51 (14.7)	0	
Fatigue	84 (23.9)	10 (2.8)	92 (26.5)	18 (5.2)	
Rash	82 (23.4)	9 (2.6)	94 (27.1)	17 (4.9)	
Back pain	80 (22.8)	2 (0.6)	66 (19.0)	1 (0.3)	
Peripheral edema	72 (20.5)	4 (1.1)	74 (21.3)	1 (0.3)	
Nausea	71 (20.2)	2 (0.6)	58 (16.7)	2 (0.6)	
Infections	305 (86.9)	124 (35.3)	266 (76.7)	95 (27.4)	
COVID-19	123 (35.0)	12 (3.4)	83 (23.9)	4 (1.2)	
Upper respiratory tract infection	111 (31.6)	2 (0.6)	87 (25.1)	6 (1.7)	
Pneumonia	64 (18.2)	37 (10.5)	38 (11.0)	21 (6.1)	

IsKia: Study Design

42 active sites; enrollment: Oct 7, 2020 - Nov 15, 2021



IsKia: Patient Characteristics

		isa-KRd n=151	KRd n=151
Age, years	Median (IQR)	61 (55-66)	60 (54-63)
Sau = 19/1	Female	72 (48)	67 (44)
Sex, n (%)	Male	79 (52)	84 (56)
Cytogenetic risk	Standard risk	115 (82)	113 (81)
as per IMWG, n (%)	High risk	25 (18)	26 (19)
High risk: t(4;14), t(14;16), or del(17p)	Missing	11	12
No. of HRCA risk:	0 HRCA	78 (56)	75 (54)
0 vs. 1 vs. 2+ HRCA, n (%)	1 HRCA	49 (35)	49 (35)
del(17p13.1), t(4;14) (p16.3;q32.3),	2+ HRCA	13 (9)	15 (11)
t(14;16) (q32.3;q23), gain(1q21), or amp(1q21)	Missing	11	12
	1	50 (35)	48 (34)
D 166 - (9/)	10	82 (58)	85 (59)
R-ISS, n (%)	10	10 (7)	10 (7)
	Missing	9	8
	1	34 (24)	35 (25)
and the second se	H.	45 (32)	47 (34)
R2-ISS, n (%)	-111	52 (37)	51 (37)
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	IV	8 (6)	6 (4)
	Missing	12	12

IsKia: Patient Disposition

- Median follow-up: 21 months
- Completed induction and consolidation:
 - Isa-KRd 83%
 - KRd 90%


	lsa-KRd n=151	KRd n=151
Patients who discontinued study treatment, n (%)	25 (17)	15 (10)
Reasons for discontinuation, n (%)	1.4	
Adverse event	9 (6)	7 (5)
Progressive disease	3 (2)	3 (2)
Medical decision	4 (3)	0
Withdrawal of consent by patient	5 (3)	4 (3)
Death	4 (3)	1 (<1)

Reasons for discontinuation, Adverse Events:

-IsaKRd: Dress Syndrome G4 (n=1); maculo-popular rash G3 (n=1); Infection (n=2, G1 n=1; G2, n=1); pancytopenia G4 (n=2); renal failure G4 (n=1); cardiovascular toxicity G2 (N=2) -KRd: anaphylactic reaction G4 (n=1); vasculitis G3 (n=1); rash G2 (n=1); Infection (n=3); pancytopenia G2 (n=1); TLS G3 (n=1); cardiovascular toxicity G3 (n=2) G4 (n=1) Deaths:

-IsaKRd : progressive disease (n=1); Infection (n=3)
-KRd: infection (n=1)

IsKia: Post-Consolidation MRD-negativity (ITT analysis)





≥VGPR after consolidation was 94% in both arms; ≥CR 74% vs 72% and sCR 64% vs 67% in the IsaKRd vs KRd arms.

High MRD compliance and sample quality (97-100% of sample evaluable at 10⁻⁵ and 10⁻⁶ cut-offs).

Consistent MRD results were detected by next-generation flow

In the logistic regression analysis, ORs, 95% CIs, and p-values were adjusted for stratification factor.





IsKia: Post-consolidation MRD-negativity by NGS

10-5	⁵ cut-off	OR (95% CI)	Interaction p	10-6	cut-off	OR (95% CI)	Interaction p
Overall	1. A.	1.67 (1.00-2.80)		Overall		2.29 (1.43-3.67)	
Cytogenetic risk as per IMWG ^a				Cytogenetic risk as per IMWG ⁴		Edendors con a	
Standard risk High risk –		1.70 (0.92-3.12) 2.30 (0.68-7.76)	0.6638	Standard risk High risk	<u> </u>	2.10 (1.22–3.61) 4.95 (1.48–16.61)	0.203
N of HRCA: 0, 1, 2+ HRCA ⁶				N of HRCA: 0, 1, 2+ HRCA ⁶	1.00		
0 HRCA -		1.60 (0.75-3.41)	0,839	0 HRCA		2.21 (1.14-4.27)	0.2982
1 HRCA -	1.00	1.86 (0.76-4.57)		1 HRCA	· · · ·	2.04 (0.88-4.70)	
2+ HRCA —		2.76 (0.52–14.56)		2+ HRCA		- 9.05 (1.57-52.14)	
R-ISS			Salia .	R-ISS		a da na da casar	6 6616
1	1	1.48 (0.58-3.75)	0.7401	1	<u> </u>	2.03 (0.89-4.63)	0.7766
11–111		1.79 (0.94–3.43)		11-111		2.35 (1.30–4.26)	
R2-ISS				R2-ISS			S inte
1	6.00	1.14 (0.36-3.60)	0.3844	-		1.76 (0.66-4.69)	0.4363
	115.00	- 3.08 (1.13-8.38) 1.49 (0.67-3.27)		III-IV	1000	3.71 (1.54-8.93) 1.92 (0.92-4.02)	
		1.45 (0.07 5.27)	÷	- 1V		1.52 (0.52 4.02)	
0,15	1	14.56		0.20	1 5	2.14	
Favors KAd	Favors Isa-	KRd		Favors KRd	Favors isa-KRd		

IsKia: Safety

	isa-KRd (n=151)		KRd (n=151)		
a survey and a survey of the	Any grade, n (%)	Grade 3-4, n (%)	Any grade, n(%)	Grade 3-4, n (%)	
Pts with ≥1 hematologic toxicity	83 (55)	61 (40)	67 (44)	46 (30)	
Anemia	32 (21)	5 (3)	28 (19)	5 (3)	
Neutropenia	62 (41)	55 (36)*	39 (26)	33 (22)*	
Thrombocytopenia	51 (34)	22 (15)	38 (25)	25 (17)	
Pts with ≥1 Non-Hematologic toxicity	136 (90)	61 (41)	129 (85)	56 (37)	
Infections (excluding COVID19)	55 (36)	23 (15)	49 (32)	17 (11)	
Asthenia/fatigue	37 (25)	5 (3)	40 (26)	3 (2)	
Dyspnea	20 (13)	2 (1)	9 (6)	1 (<1)	
Rash	33 (22)	5 (3)	40 (26)	5 (3)	
Peripheral neuropathy	22 (15)	0	25 (17)	0	
Infusion-related reactions	30 (20)	5 (3)	2 (1)	0	
Cardiac disorders	11 (7)	1 (<1)	19 (13)	5 (3)	
Vascular disorders	29 (19)	7 (5)	33 (22)	15 (10)	
Hypertension	5 (3)	2 (1)	6 (4)	3 (2)	
Thromboembolism	12 (8)	4 (3)	16 (11)	9 (6)	
Gastrointestinal disorders	79 (52)	10 (7)	73 (48)	8 (5)	
Nausea	36 (24)	4 (3)	31 (21)	2 (1)	
Vomiting	18 (12)	2 (1)	12 (8)	1 (<1)	
Diarrhea	41 (27)	6 (4)	37 (25)	5 (3)	

_	SARS-CoV-	2 infection	1			
isa-KRd	(n=151)	KRd (n=151)				
Any grade, n (%)	Grade ≥3, n (%)	Any grade, n (%)	Grade ≥3, n (%)			
39 (26)	3 (2)	28 (19)	2 (1)			

*p-value =0.008

Conclusion

D-VRd produced deep and durable responses in ASCT-eligible, NDMM patients versus VRd.

- 48-month PFS: 84.3% vs 67.7%, **p<0.0001**
- ≥CR: 87.9% vs 70.1%, **p<0.0001**
- Overall MRD-negativity: 75.2% vs 47.5%, p<0.0001

Rates of MRD-negativity improved during maintenance, and 64% of patients were able to discontinue daratumumab after achieving MRD-negativity with at least two years of maintenance.

In the primary analysis of the IsKia trial, Isa-KRd improved post-consolidation MRD negativity vs KRd.

- Post-Consolidation MRD-negativity:
 - MRD-negativity, 10⁻⁵: 77% vs 67%, p=0.049
 - MRD-negativity, 10⁻⁶: 67% vs 48%, p<0.001

1-year sustained MRD negativity data is expected later this year.

Application to current practice


For transplant eligible

- Use quadruplet for induction (eg RVD dara)
- Consider consolidation if MRD positive post BMT
- Consider doublet for maintenance if MRD positive or high risk disease after consolidation

For transplant ineligible

- Use CD 38/ len containing triplet as induction for STD risk(DRd)
- Use quadruplet for high risk (DRVd lite)
- Consider doublet for maintenance in MRD positive after 8-12 months of induction therapy


Novel Therapies in Relapsed/Refractory Myeloma



BCMA-Targeting CAR-T

- Ide-cel: Approved Mar 2021
- Cilta-cel: Approved Feb 2022

Bispecific T-Cell Engagers



BCMA-Targeting Bispecifics

- Teclistamab: Approved Oct 2022
- Elranatamab: Approved Aug 2023

GPRC5D-Targeting Bispecific

• Talquetamab: Approved Aug 2023

Current indications for both CAR-T and Bispecifics in RRMM


Triple class exposed: PI, IMID & anti-CD38+ monoclonal antibody

Progressing/Relapsed disease

≥4 prior lines of therapy

KARMMA-3 and CARTITUDE-4, CAR-T outperforms SOC - ?could lead to earlier indication

P Rodriguez-Otero et al. N Engl J Med 2023;388:1002-1014.




J San-Miguel et al. N Engl J Med 2023;389:335-347.

Parameter	KarMMa-3		CARTITUDE-4			
	lde-Cel	SOC	Cilta-Cel	SOC		
Inclusion criteria	2-4 prior lines inc	luding PI + IMiD + Dara	1-3 prior lines, Len-refra	actory		
Prior lines of therapy, n, median (range)	3 (2-4)	3 (2-4)	2 (1-3)	2 (1-3)		
Refractory to anti-CD38 antibodies, n	242 (95)	123 (93)	50 (24)	46 (22)		
(%)						
Triple-class refractory, n (%)	164 (65)	89 (67)	30 (14)	33 (16)		
ORR, n (%)	181 (71)	55 (42)	176 (85)	142 (67)		
::: CR, n (%)	98 (39)	7 (5)	152 (73)	46 (22)		
::: VGPR, n (%)	153 (60)	20 (16)	169 (81)	96 (46)		
MRD-negative 10⁻⁵, n (%)	51/254 (20)	1 (1)	126/144 (88)	33/101 (33)		
DOR, mo, median	14.8	9.7	Not reached; 85% at 12 mo	Not reached; 63% at 12 mo		
PFS, mo, median	13.3	4.4	Not reached; 76% at 12 mo	0 11.849% at 12 mo CINE		

Future of CAR-T in MM

- Newly diagnosed transplant eligible
- Newly diagnosed transplant ineligible
- Novel CAR-T (GPRC5D CAR/Dual BCMA-GPRC5D CAR-T, ddBCMA CAR)
- Consolidation post Auto in suboptimal response and >=1 prior lines

KarMMa-2 cohort 2c: efficacy and safety of idecabtagene vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation




MRD negativity in all patients and those in \geq CR In patients who achieved \geq CR, sustained MRD negativity at 10⁻⁵ was observed in 69.6% (16 of 23, 95% CI 49.1–84.4) at 12 months; of these 16 patients, 11 sustained MRD negativity at 24 months (2 patients had no MRD data available, and 3 were indeterminate)

In all evaluable patients, sustained MRD negativity at 10⁻⁵ was observed in 60.7% (17 of 28; 95% CI 42.4–76.4) at 12 months

24 months PFS of 83.1%


Bispecific T-Cell Engagers




Overview of Teclistamab

Teclistamab is a BCMA-directed CD3 T-cell engager approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including:


- Proteasome inhibitor
- Immunomodulatory agent
- Anti-CD38 monoclonal antibody



MajesTEC-1: Trial Design and ORR




Treatment history	N = 165
≤3 prior lines of treatment	74.4 (32/43)
>3 prior lines of treatment	59.0 (72/122)
High-risk cytogenetics and/or EMD	53.3 (32/60)



Usmani et al., ASCO 2023

MajesTEC-1: Duration of Response



Parameter, mo (95% CI)	All patients (n=165)	≥ CR (n=75)
Median PFS	11 (9-16)	27 (23-NE)
Median OS	22 (15-NE)	NR (NE-NE)

Median time to ≥CR: 4.6 mo (range 1.6-18.5)


42 patients evaluable for MRD at Day 100

• Rate of uMRD (10⁻⁵): 81%

54 patients evaluable at any point

• Rate of uMRD (10⁻⁵): 81.5%

MajesTEC-1: Deep Responses with Q2W or Q4W Dosing




104/165 pts responded to RP2D of Teclistamab

- 63 pts switched to Q2W dosing
- 9 pts switched to Q4W dosing

After switching, mDOR not yet reached

- 68.7% (95% CI: 53.6-79.7%) remained in response for 2+ years from time of first response
- 42/63 responders maintained a response after switching to less frequent dosing



MajesTEC-1: Safety

Median treatment duration: 8.5 mo (range: 0.2-24.4)

- 1 AE led to dose reduction
- 8 AEs led to discontinuation(5 due to infection)
- 7 treatment-related deaths (4 due to COVID-19)
- All cases of ICANS resolved

<u>CRS</u>

• Any Grade: 72.1%


• Grade 3 or 4: 0.6%

ICANS

- Any Grade: 3%
- No grade 3 or 4 ICANS events

AEs ≥20%, n (%)	Any Grade	Grade 3/4
Hematologic		
Neutropenia	118 (71.5)	108 (65.5)
Anemia	90 (54.5)	62 (37.6)
Thrombocytopenia	70 (42.4)	37 (22.4)
Lymphopenia	33 (20.0)	15 (9.1)
Non-Hematologic		
Infection	132 (80.0)	91 (55.2)
CRS	119 (72.1)	1 (0.6)
ICANS	5 (3.0)	0
Diarrhea	56 (33.9)	6 (3.6)
Pyrexia	52 (31.5)	1 (0.6)
Fatigue	48 (29.1)	4 (2.4)
Nausea	45 (27.3)	1 (0.6)
Injection site erythema	43 (26.1)	0
Headache	40 (24.2)	1 (0.6)
Arthralgia	42 (25.5)	1 (0.6)
Constipation	36 (21.8)	0
Cough	44 (26.7)	0

MajesTEC-1: Reduction in Grade ≥3 Infection




Pts who switched to Q2W by 1 year had fewer grade \geq 3 treatment-emergent infections compared to those who remained on QW (15.6% vs 33.3%)

Overview of Elranatamab


Elranatamab is another bispecific BCMAdirected CD3 T-cell engager

On **August 14, 2023**, Elranatamab received FDA approval for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy



MagnetisMM-3: Trial Design


- MagnetisMM-3 (NCT04649359) is an open-label, multicenter, non-randomized, phase 2 study
 - Interim analysis data-cut off: March 23, 2022



First 94 patients who received ≥1 dose of elranatamab

Pharmacokinetics

MagnetisMM-3: Response




Subgroup	Patients (n)	ORR (95% CI)
All patients	123	1
Baseline cytogenetics		(
High risk Standard risk	31	8
Standard risk	83	
Baseline extramedullary di	sease	
Yes	39	
No	84	
Baseline bone marrow plas	ema colle	
<50%	89	
<50% ≥50%	26	
	20	1
R-ISS disease stage	00	E and a
1-2 3	96 19	
3	19	
Number of prior lines of th	erapy	
2-3	26	
≥4	97	
Age (years)		
<65	43	
≥65	80	
<75	99	
≥75	24	
Sex		
Male	68	
Female	55	
Race	70	
White Others	72 26	
	20	1
Penta-refractory disease		
Yes	52 71	the second se
No	71	
ECOG		
0	45	
1-2	78	
	1	1 1 1
	0	25 50 75

Percentage

Lesokin et al., Nat Med 2023

MagnetisMM-3: PFS and OS

PFS



	Overall Population mo (95% Cl)	Pts with ≥CR mo (95% Cl)
Median Duration of Response	NE (12.0 – NE)	
Median PFS	NE (9.9 – NE)	NE (NE – NE)
Median OS	NE (13.9 – NE)	NE (NE – NE)

Lesokin et al., Nat Med 2023

OS

MagnetisMM-3: Safety

Grade 3 or 4 treatment-emergent AEs were reported in 87 patients (70.7%).

Dose Interruption or Reduction

Dose interruption: 77.2%

- Infection: 50.4%
- Hematologic: 40.7%
- Neutropenia: 35%

Dose reduction: 28.5%

Freatment-Emergent Adverse Effect, n (%)	Any grade	Grade 3/4
Any TEAE	123 (100%)	87 (70.7%)
Hematologic		
Anemia	60 (48.8%)	46 (37.4%)
Neutropenia	60 (48.8%)	60 (48.8%)
Thrombocytopenia	38 (30.9%)	29 (23.6%)
Lymphopenia	33 (26.8%)	31 (25.2%)
Non-Hematologic		
Cytokine release syndrome	71 (57.7%)	0
Diarrhea	52 (42.3%)	2 (1.6%)
Fatigue	45 (36.6%)	4 (3.3%)
Decreased appetite	41 (33.3%)	1 (0.8%)
Pyrexia	37 (30.1%)	5 (4.1%)
COVID-19 related	36 (29.3%)	19 (15.4%)
Injection site reaction	33 (26.8%)	0
Nausea	33 (26.8%)	0
Hypokalemia	32 (26.0%)	13 (10.6%)
Cough	31 (25.2%)	0
Headache	29 (23.6%)	0
	Lesokin et al., Na	at Med 2023

Dosing Schedules


Elranatamab FDA Label

Teclistamab FDA Label

ELREXFIO E	osing Schedule (2.2)	P.
Day	ELREXFIO	Dose
Day 1	Step-up dose 1	12 mg
Day 4	Step-up dose 2	32 mg
Day 8	First treatment dose	76 mg
One week after first treatment dose and weekly thereafter through week 24	Subsequent treatment doses	76 mg
Week 25 and every 2 weeks thereafter	Subsequent treatment doses	76 mg
	Day 1 Day 1 Day 4 Day 8 One week after first treatment dose and weekly thereafter through week 24 Week 25 and every	Day 1Step-up dose 1Day 4Step-up dose 2Day 4Step-up dose 2Day 8First treatment doseOne week after first treatment dose and weekly thereafter through week 24Subsequent treatment dosesWeek 25 and everySubsequent

TI	ECVAYLI Recommend	ed Dosing Schedul	e (2.1)
Dosing Schedule	Day	Dose	
Store and	Day 1	Step-up dose 1	0.06 mg/kg
Step-up Dosing	Day 4	Step-up dose 2	0.3 mg/kg
Schedule	Day 7	First treatment dose	1.5 mg/kg
Weekly Dosing Schedule	One week after first treatment dose and weekly thereafter	Subsequent treatment doses	1.5 mg/kg once weekly


Q2W and Q4W Explored in MajesTEC-1




Overview of Talquetamab

Talquetamab is a novel bispecific GPRC5Ddirected CD3 T-cell engager


On **August 9, 2023**, Talquetamab received FDA approval for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy



MonumenTAL-1: Study Design



MonumenTAL-1: Objective Response Rate



Triple-class refractory: 72.6% (95% Cl, 63.1–80.9) and 71.0% (95% Cl, 61.1–79.6)


Penta-drug refractory: 71.4% (95% Cl, 55.4–84.3) and 70.6% (95% Cl, 52.5–84.9)

ORR was consistent across subgroups including baseline ISS stage III disease, baseline cytogenetic risk, number of prior therapies, refractoriness to prior therapy, and belantamab exposure, except among patients with baseline plasmacytomas


Timing, months	0.4 mg/kg SC QW n=143	0.8 mg/kg SC Q2W n=145
Median (range) follow-up, efficacy	14.9 (0.5₅–29.0)	8.6 (0.2₅–22.5)
Median (range) time to first response	1.2 (0.2–10.9)	1.3 (0.2–9.2)
Median (range) time to best response	2.2 (0.8–12.7)	2.7 (0.3–12.5)

MonumenTAL-1: Duration of Response

DOR, 0.4 mg/kg SC QW^a



DOR, 0.8 mg/kg SC Q2W^b



mPFS: 7.5 months (95% CI: 5.7–9.4; 33% censored)

mPFS: 11.9 months (95% CI: 8.4–NE; 61% censored)

Chari et al., ASH 2022

MonumenTAL-1: Adverse Effects

Most high-grade AEs were cytopenias

Infections

0.4 mg/kg QW

- Any Grade: 57.3%
- Grade 3/4: 16.8%
- Opportunistic Infection: 3.5%
- COVID-19: 9.1%
 - Grade 3/4: 0.7%


0.8 mg/kg Q2W

- Any Grade: 50.3%
- Grade 3/4: 11.7%
- Opportunistic Infection: 2.8%
- COVID-19: 11.0%
 - Grade 3/4: 2.1%


AEs (≥20% of any RP2D	0.4 mg/kg SC QW (n=143) Median Follow-up, 11.0 months		0.8 mg/kg SC Q2W (n=145) Median Follow-up, 5.1 months	
cohort)	Any Grade n (%)	Grade 3/4 (%)	Any Grade (%)	Grade 3/4 (%)
CRS	113 (79.0)	3 (2.1)	105 (72.4)	1 (0.7)
Anemia	64 (44.8)	45 (31.5)	57 (39.3)	36 (24.8)
Neutropenia	49 (34.3)	44 (30.8)	41 (28.3)	32 (22.1)
Lymphopenia	40 (28.0)	37 (25.9)	38 (26.2)	37 (25.5)
Thrombocytopenia	39 (27.3)	29 (20.3)	39 (26.9)	24 (16.6)
Skin-related AEs ^d	80 (55.9)	0	98 (67.6)	1 (0.7)
Nail-related AEs ^e	74 (51.7)	0	63 (43.4)	0
Dysgeusia ^f	69 (48.3)	NA	67 (46.2)	NA
Rash-related AEs ^g	56 (39.2)	2 (1.4)	39 (26.9)	8 (5.5)
Weight decreased	57 (39.9)	3 (2.1)	47 (32.4)	2 (1.4)
Pyrexia	53 (37.1)	4 (2.8)	35 (24.1)	1 (0.7)
Asthenia	37 (25.9)	3 (2.1)	13 (9.0)	2 (1.4)
Dry mouth	36 (25.2)	0	53 (36.6)	0
Diarrhea	34 (23.8)	3 (2.1)	32 (22.1)	0
Dysphagia	34 (23.8)	0	33 (22.8)	3 (2.1)
Fatigue	32 (22.4)	5 (3.5)	29 (20.0)	1 (0.7)
Decreased appetite	25 (17.5)	2 (1.4)	29 (20.0)	2 (1.4)

MonumenTAL-1: Prospective Dose Reduction Maintains Response

- Patients with prospective dose reduction were required to be in response (n=19)
- Dose reduction occurred at a median of 3.1 mo (range, 2.3 – 4.2) relative to treatment start



	Prospective Dose Reduction Cohort (n=19)	0.8 mg/kg Q2W Registrational Cohort (n=145)
Median PFS, mo (95% CI)	13.2 (8.8 – NE)	14.2 (9.6 – NE)
12-mo PFS rate, %	50.1%	54.4%
Median DOR, mo (95% CI)	NE (8.3 – NE)	NE (13.0 – NE)




Chari et al. ASH 2023.

Conclusion

- CAR-T and bispecific antibodies are excellent targeted therapy options for RRMM patients who have failed at least four prior lines of therapy.
- There are now two FDA-approved, BCMA-directed BsAbs. Teclistamab and elranatamab have similar efficacy and safety profiles and are both excellent, off-the-shelf options.
- Talquetamab is the first FDA-approved GPRC5D-targeting agent in RRMM and is effective in patients who have developed resistance to BCMAdirected therapies.
- Infections, CRS, and ICANS are seen with all three agents.
- Talquetamab is associated with lower rate of infections, but patients experience unique skin, nail, and taste-related toxicities. Dose reduction appears to be an effective strategy to manage GPRC5D-related toxicity.

and more to come....



Rajkumar SV, et al. Am J Hematol. 2020;95:548; Su C, et al. J Hematol Onco. 2021;14:115.

Acknowledgments:

Our Patients, their families, and care-givers

Melissa Alsina M.D. Rachid Baz M.D. Kenneth H. Shain M.D., Ph.D. Jason Brayer M.D., Ph.D Brandon Blue M.D. William S Dalton Ph.D, M.D. Taiga Nishihori M.D. Hien Liu M.D.

Doris Hansen M.D. Lionel Ochoa-Bayona M.D. Ciara Freeman M.D., Ph.D. Omar Casteneda-Puglianini M.D. Ariel Grajales-Cruz M.D. Fred Locke M.D., Ph.D. Jinming Song M.D. John Koomen Ph.D. Ariosto Silva PH.D Dung-Tsa Chen Ph.D. John Cleveland Ph.D Nancy Gillis-Johnson Ph.D. Lauren Peres Ph.D. Conor Lynch Ph.D. Jamie Teer Ph.D. Xuefeng Wang Ph.D. Johnphil Kim Ph.D.

Christine Simonelli Dana Spiak Ann Nelson Jammie Freeman Ethvl Matta Samantha Seitzler Buffy Allen

Heather Warner **Beth Finley-Oliver**

Elizabeth Howard Alicin Roop Sabrina Hasan Sonila Toska Gabriel Cubillos Valeria Burchard

Gabriella Acosta

Gabriel De Avilla Ken Harada Tajj Mainor **Bailey Spence** Raghu Reddy-Alugubelli

Shain Lab: Mark Meads PhD Dario Magaletti Alex Achille David Noves Alex Achille

Silva Lab:

Maria Silva Praneeth Reddy Sudulagunta, PhD Rafael Renatino-Canevarolo, PhD





PHYSICAL SCIENCES in ONCOLOGY





Pentecost Myeloma Research Center



Questions?

Melissa.alsina@moffitt.org